Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
FACS analysis of Nectin-4 on HEK293/Human Nectin-4 Stable Cell Line.
FACS assay shows that Anti-Nectin-4 antibody can bind to HEK293/Human Nectin-4 Stable Cell Line. HEK293/Human Nectin-4 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).
Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Cynomolgus Nectin-4, His Tag (Cat. No. NE4-C52H4) with an affinity constant of 824 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Enfortumab vedotin | DLE8519RWM; ASG-22ME; AGS-22M6E; ASG-22M6E; ASG-22CE; AGS-22ME; AGS-22C3; AGS-M6; AGS-22C3E | Approved | Agensys Inc | Padcev | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Enfortumab vedotin | DLE8519RWM; ASG-22ME; AGS-22M6E; ASG-22M6E; ASG-22CE; AGS-22ME; AGS-22C3; AGS-M6; AGS-22C3E | Approved | Agensys Inc | Padcev | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
9MW2821 | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
BT-8009 | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University, The Sixth Affiliated Hospital Of Wenzhou Medical University | Solid tumours | Details | |
ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Pelvic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Neoplasms | Details |
SKB-410 | SKB410; SKB-410 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
SHR-A2102 | SHR-A2102 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours | Details |
9MW2821 | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
BT-8009 | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University, The Sixth Affiliated Hospital Of Wenzhou Medical University | Solid tumours | Details | |
ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Pelvic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Neoplasms | Details |
SKB-410 | SKB410; SKB-410 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
SHR-A2102 | SHR-A2102 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.